

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Declaration for Patent Application

As a named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated next to my name;

I believe I am the original, first and sole inventor (if only one name is listed) or an original, first and joint inventor (if plural names are listed in the signatory page(s) commencing at page 3 hereof) of the subject matter which is claimed and for which a patent is sought on the invention entitled

ANTI-TNF ANTIBODIES AND METHOTREXATE

IN THE TREATMENT OF AUTOIMMUNE DISEASE

the specification of which (check one)

☐ is attached hereto.

☒ was filed on August 1, 1996 as United States Application
Serial No. 08/690,775.

and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is known by me to be material to patentability as defined in 37 C.F.R. §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

<u>Prior Foreign Application(s)</u>			Priority Not Claimed []
_____ (Number)	_____ (Country)	_____ (Day/Month/Year filed)	[]
_____ (Number)	_____ (Country)	_____ (Day/Month/Year filed)	[]
_____ (Number)	_____ (Country)	_____ (Day/Month/Year filed)	[]

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

(Application Number)

(Filing Date)

(Application Number)

(Filing Date)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States

application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information known by me to be material to patentability as defined in 37 C.F.R. §1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

<u>08/607,419</u> (Application Serial No.)	<u>February 28, 1996</u> (Filing date)	<u>pending</u> (Status, patented, pending, abandoned)
<u>PCT/GB94/00462</u> (Application Serial No.)	<u>March 10, 1994</u> (Filing date)	<u>pending</u> (Status, patented, pending, abandoned)
<u>PCT/GB93/02070</u> (Application Serial No.)	<u>October 6, 1993</u> (Filing date)	<u>pending</u> (Status, patented, pending, abandoned)
<u>07/958,248</u> (Application Serial No.)	<u>October 8, 1992</u> (Filing date)	<u>abandoned</u> (Status, patented, pending, abandoned)

As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

I also hereby grant additional Powers of Attorney to the following attorneys and/or agents to file and prosecute an international application under the Patent Cooperation Treaty based upon the above-identified application, including a power to meet all designated office requirements for designated states:

David E. Brook	Reg. No. 22,592	Thomas O. Hoover	Reg. No. 32,470
James M. Smith	Reg. No. 28,043	Alice O. Carroll	Reg. No. 33,542
Leo R. Reynolds	Reg. No. 20,884	N. Scott Pierce	Reg. No. 34,900
Patricia Granahan	Reg. No. 32,227	Richard A. Wise	Reg. No. 18,041
Mary Lou Wakimura	Reg. No. 31,804	Carolyn S. Elmore	Reg. No. 37,567
		Helen Lee	Reg. No. 39,270

all of Hamilton, Brook, Smith and Reynolds, P.C., Two Militia Drive, Lexington, Massachusetts 02173.

Send correspondence to: David E. Brook, Esq., Hamilton, Brook, Smith & REYNOLDS, Two Militia Drive, Lexington, Massachusetts 02173-4799

Direct telephone calls to: David E. Brook, Esq.

(617) 861-6240

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole

or first inventor Marc Feldmann

Inventor's

Signature  Date 20 Sept 96

Residence 2 Church Road

Highgate, London N6 4QT, ENGLAND

Citizenship Australia

Post Office Address Same as above

Full name of second joint

inventor, if any Ravinder N. Maini

Second Inventor's

Signature RNMW Date 23/9/96

Residence 151 Castelnau

Barnes, London SW13 9EW, ENGLAND

Citizenship United Kingdom

Post Office Address Same as above

Full name of third joint

inventor, if any _____

Third Inventor's

Signature _____ Date _____

Residence _____

Citizenship _____

Post Office Address _____

Full name of fourth joint

inventor, if any _____

Fourth Inventor's

Signature _____ Date _____

Residence _____

Citizenship _____

Post Office Address _____

Full name of fifth joint

inventor, if any _____

Fifth Inventor's

Signature _____ Date _____

Residence _____

Citizenship _____

Post Office Address _____

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Marc Feldmann and Ravinder N. Maini

Application No.: 08/690,775 Group Art Unit: 1644

Filed: August 1, 1996 Examiner: P. Gambel

Title: ANTI-TNF ANTIBODIES AND METHOTREXATE IN THE TREATMENT
OF AUTOIMMUNE DISEASE

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231	
on <u>4/23/01</u>	<u>Sandra Jammal</u>
Date	Signature
<u>Sandra Jammal</u>	
Typed or printed name of person signing certificate	

REVOCATION OF POWERS OF ATTORNEY
AND APPOINTMENT OF NEW ATTORNEYS AND/OR AGENTS

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The Kennedy Institute of Rheumatology, a Corporation duly organized under the laws of the United Kingdom, is the assignee of the entire right, title and interest in the above-identified application. The Kennedy Institute of Rheumatology hereby appoints:

John P. White, Esq.
Registration No.: 28,678
Cooper & Dunham
1185 Avenue of the Americas
New York, New York 10036

to prosecute the above-identified application and any divisions or continuations thereof and to conduct all business in the United States Patent and Trademark Office. All previously granted Powers of Attorney are hereby revoked.

Certification under 37 C.F.R. §3.73(b) is submitted herewith.

The Kennedy Institute of Rheumatology

By Rnmami

Ravinder N. Maini

Ravinder N. Maini
Honorary
 Title: / Director, *and Trustee* *RNM*
 The Kennedy Institute of Rheumatology

Date 18/4/2001

CERTIFICATE UNDER 37 C.F.R. § 3.73(b)Applicants: Marc Feldmann and Ravinder N. MainiApplication No.: 08/690,775 Filed: August 1, 1996For: ANTI-TNF ANTIBODIES AND METHOTREXATE IN THE TREATMENT OF AUTOIMMUNE DISEASEThe Kennedy Institute of Rheumatology, a Corporation,
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

certifies that it is

- A. ☒ the assignee of the entire right, title and interest in the patent application identified above.
- B. ☐ an assignee together with [] of the entire right, title and interest in the patent application identified above. A separate Certificate under 37 CFR § 3.73(b) is attached.

The right, title and interest of the above-named assignee in the patent application identified above is established by virtue of:

- A. ☒ An assignment from the inventors of the patent application identified above. The assignment was recorded in the Patent and Trademark Office at Reel 8168, Frame 0822-0824, or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s) of the patent application identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are attached.

☐ Copies of assignments or other documents in the chain of title are attached.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: 15/4/2001Name: Ravinder N. MainiTitle: Director, The Kennedy Institute of RheumatologySignature: RN Maini